These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10313738)

  • 1. Economic considerations in technology assessment: the case of genetic disease.
    Lairson DR; Swint JM
    Health Policy; 1988; 9(3):309-15. PubMed ID: 10313738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethical Issues with Genetic Testing for Tay-Sachs.
    Clayton T
    J Christ Nurs; 2017; 34(4):246-249. PubMed ID: 28902054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic screening: triumphs, problems, and controversies.
    Natowicz MR; Alper JS
    J Public Health Policy; 1991; 12(4):475-91. PubMed ID: 1802891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economic returns to community and hospital screening programs for a genetic disease.
    Swint JM; Shapiro JM; Corson VL; Reynolds LW; Thomas GH; Kazazian HH
    Prev Med; 1979 Jul; 8(4):463-70. PubMed ID: 112594
    [No Abstract]   [Full Text] [Related]  

  • 5. Improving population health or the population itself? Health technology assessment and our genetic future.
    Bassett K; Lee PM; Green CJ; Mitchell L; Kazanjian A
    Int J Technol Assess Health Care; 2004; 20(2):106-14. PubMed ID: 15209171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost of choice: a price too high in the triple screen for Down syndrome.
    Elkins TE; Brown D
    Clin Obstet Gynecol; 1993 Sep; 36(3):532-40. PubMed ID: 7691458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical technology assessment: adequate questions, appropriate methods, valuable answers.
    Glasser JH; Chrzanowski RS
    Health Policy; 1988; 9(3):267-76. PubMed ID: 10312551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ovrselling of genetic anxiety.
    Goodman MJ; Goodman LE
    Hastings Cent Rep; 1982 Oct; 12(5):20-7. PubMed ID: 7174291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk targetting: an approach to cost-containment.
    Charny MC; Farrow SC
    Health Policy; 1986; 6(4):363-72. PubMed ID: 10311785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the effectiveness of supply-side cost-containment measures.
    Garrison LP
    Health Care Financ Rev Annu Suppl; 1991; ():13-20. PubMed ID: 10117115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allocating resources.
    Drummond MF
    Int J Technol Assess Health Care; 1990; 6(1):77-92. PubMed ID: 2113892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A primer on economic evaluations related to expansion of newborn screening for genetic and metabolic disorders.
    Hubbard HB
    J Obstet Gynecol Neonatal Nurs; 2006; 35(6):692-9. PubMed ID: 17105633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Tay-Sachs disease screening program in the U.S. as a model for the control of genetic disease: an historical view.
    Edelson PJ
    Health Matrix Clevel; 1997; 7(1):125-33. PubMed ID: 10167171
    [No Abstract]   [Full Text] [Related]  

  • 14. Ashkenazi Jewish population screening for Tay-Sachs disease: the international and Australian experience.
    Lew RM; Burnett L; Proos AL; Barlow-Stewart K; Delatycki MB; Bankier A; Aizenberg H; Field MJ; Berman Y; Fleischer R; Fietz M
    J Paediatr Child Health; 2015 Mar; 51(3):271-9. PubMed ID: 24923490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The allocation of medical resources by physicians.
    Relman AS
    J Med Educ; 1980 Feb; 55(2):99-104. PubMed ID: 6766505
    [No Abstract]   [Full Text] [Related]  

  • 16. Sounding Boards. What is CBA/CEA, and why are they doing this to us?
    Fuchs VR
    N Engl J Med; 1980 Oct; 303(16):937-8. PubMed ID: 6774250
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness analysis and innovation.
    Jena AB; Philipson TJ
    J Health Econ; 2008 Sep; 27(5):1224-36. PubMed ID: 18619695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tay-Sachs disease carrier screening: a 21-year experience.
    D'Souza G; McCann CL; Hedrick J; Fairley C; Nagel HL; Kushner JD; Kessel R
    Genet Test; 2000; 4(3):257-63. PubMed ID: 11142756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of prenatal screening.
    Brock DJ
    Birth Defects Orig Artic Ser; 1982; 18(3 Pt A):109-20. PubMed ID: 6215071
    [No Abstract]   [Full Text] [Related]  

  • 20. Knowledge and attitudes toward Tay-Sachs disease among a college student population.
    Austein CF; Seashore MR; Mick SS
    Yale J Biol Med; 1981; 54(5):345-54. PubMed ID: 7336765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.